We have multiple pending patents for novel first- and second-generation drugs with a focus on safety and efficacy, combined with an expert R&D team and cutting-edge research facilities in Canada and the U.S.

We’ve partnered with top global research organizations to investigate multiple drug candidates offering the potential for increased efficacy and additional improvements. Initial clinical trials will target nicotine dependence and PTSD.

Technology is a key component of our business strategy, and we’re leveraging AI/ML technology to screen billions of molecules to identify promising new compounds. We also offer a virtual health platform to support patients throughout their mental health journey.